We are live on ! Find out more
KTTAW icon

Pasithea Therapeutics Warrants

5 hedge funds and large institutions have $27K invested in Pasithea Therapeutics Warrants in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more funds holding

Funds holding: 25 (+3)

1.36% more ownership

Funds ownership: 4.86%6.22% (+1.4%)

44% less capital invested

Capital invested by funds: $48.7K → $27K (-$21.7K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
5
Holders Change
+3
Holders Change %
+150%
% of All Funds
0.08%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
Reduced
1
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change
Change in
Stake
AC
1
Armistice Capital
New York
$15.8K -1 -0%
WAM
2
Warberg Asset Management
Illinois
$6.23K
KC
3
Kepos Capital
New York
$5K +$9.9K +334,600 New
CS
4
Clear Street
New York
$3 +$6 +200 New
Bank of America
5
Bank of America
North Carolina
$2 +$3 +100 New

KTTAW Hedge Fund Activity: Q2 2023 in Review

5 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q2 2023, worth a combined $27K — down 44% from $48.7K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new KTTAW positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Clear Street, opening a new position worth an estimated $6.

  • 5 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q2 2023, up from 2 in Q1 2023.
  • Funds reported $27K of Pasithea Therapeutics Warrants stock for Q2 2023, down 44% quarter-over-quarter.
  • 3 funds opened new Pasithea Therapeutics Warrants positions in Q2 2023 and 0 closed out, a net change of +3 holders.
  • The largest Pasithea Therapeutics Warrants buyer in Q2 2023 was Clear Street, an estimated $6 added.

Based on aggregated 13F filings for Q2 2023.